# Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

> **NCT01484119** · PHASE3 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 630 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** ACT-129968
- **DRUG:** Placebo
- **DRUG:** Cetirizine

## Key facts

- **NCT ID:** NCT01484119
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-03
- **Target enrollment:** 630 (ACTUAL)
- **Last updated:** 2018-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484119, "Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01484119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*